Today: 2 July 2026
Critical Metals (CRML) stock jumps 10% as Saudi rare-earth talks resurface in filing
23 January 2026
1 min read

Critical Metals (CRML) stock jumps 10% as Saudi rare-earth talks resurface in filing

New York, Jan 23, 2026, 15:56 EST — Regular session

  • Critical Metals shares jumped roughly 10% during afternoon trading, after a volatile session earlier in the day
  • A recent filing revealed a non-binding Saudi MoU alongside four non-binding offtake term sheets linked to Tanbreez
  • Traders are focused on binding contracts and any follow-up disclosures following this week’s company update

Shares of Critical Metals Corp jumped roughly 10% Friday, continuing a volatile streak. Investors are zeroing in on the company’s recent updates about rare-earth processing and ongoing sales discussions linked to its Tanbreez project.

This shift is crucial as Critical Metals aims to build a complete pipeline from mining to refined output. The market swiftly reacts to any signs of locked-in buyers or processing capabilities in a sector notorious for execution challenges.

Rare earths make up a tiny slice of the mining sector by volume, yet they’re key to magnets and parts in defense gear and electrification. A more straightforward route to processing and steady sales could shift how traders assess financing and project timelines.

Critical Metals closed at $20.34, gaining $1.88 from the previous $18.46. On Friday, shares fluctuated between $16.90 and $20.73, with volume exceeding 39 million shares.

Late Wednesday, the company disclosed in a Form 6-K that it signed a non-binding memorandum of understanding (MoU) with Saudi Arabia’s Tariq Abdel Hadi Abdullah Al‑Qahtani & Brothers Company. The goal: to explore one or more joint ventures for a processing and refining facility in the kingdom. The filing also confirmed Critical Metals holds a 42% equity stake in the Tanbreez Green Rare Earth Mine. (Source: )

The filing also revealed the company has secured four non-binding term sheets for offtake of rare-earth concentrate from Tanbreez. An offtake refers to an agreement to sell future production, while a term sheet outlines initial terms. The company cautioned there’s no certainty these will turn into binding deals on favorable terms—or at all.

Shares of U.S.-listed critical-minerals peers edged higher, though gains were modest. MP Materials added roughly 1%, with Energy Fuels climbing around 4.5%.

Earlier this month, Critical Metals announced it had signed a non-binding term sheet to establish a 50/50 joint venture with the same Saudi group for a rare earth processing plant in Saudi Arabia. The company confirmed it would neither issue equity nor take on debt related to this agreement. Tony Sage, chairman of Critical Metals, described the deal as a “transformational milestone.” Abdulmalik Tariq Al‑Qahtani, CEO of the Saudi group, highlighted the “strong opportunity” to collaborate with U.S. partners. (Source: Company statement)

On Jan. 15, Reuters reported that Critical Metals expects the project to aid in locking down customers and financing. The company had pre-sold 75% of its planned output by that point. (Source: )

Friday’s trading spotlighted the risks in the story. The latest MoU and offtake term sheets remain non-binding, and any processing expansion hinges on securing permits, engineering plans, and financing — plenty could go sideways before any metal changes hands.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Viking Therapeutics (VKTX) Falls After Lower Earnings Outlook
    July 1, 2026, 7:43 PM EDT. Viking Therapeutics (VKTX) dropped 3.92% to $37.48. That trailed the S&P 500, which edged down 0.22%. The stock is still up 33.19% over the last month, beating the Medical sector's 6.47% gain. But attention has turned to earnings. Analysts now see EPS sinking 108.62% year over year to -$1.21. Full-year forecasts call for EPS of -$4.70 and no revenue growth. The stock sits at Zacks Rank #4 (Sell), with its Medical - Biomedical and Genetics group in the lowest 37% by Zacks Industry Rank. Recent negative revisions point to more uncertainty, as investors watch earnings estimates and reactions in the market.
AMD stock rises as Intel supply warning jolts chip trade; earnings next in focus
Previous Story

AMD stock rises as Intel supply warning jolts chip trade; earnings next in focus

Exxon Mobil stock price rises after-hours as XTO shops $1 billion Eagle Ford assets ahead of Q4 results
Next Story

Exxon Mobil stock price rises after-hours as XTO shops $1 billion Eagle Ford assets ahead of Q4 results

Go toTop